VUMC | MedPath

AI-Driven Clinical Alert System Shows 10x Improvement in Suicide Risk Screening Rates

4 months ago

• A Vanderbilt study demonstrates that AI-powered interruptive alerts led to 42% suicide risk assessment completion rate compared to 4% with passive alerts in neurology clinics. • The VSAIL model analyzes electronic health records to identify high-risk patients, flagging only 8% of total visits for targeted screening, making implementation feasible in busy clinical settings. • Research validates the system's efficiency in neurology clinics, where certain conditions correlate with increased suicide risk, with no reported adverse events during the 30-day follow-up period.

Elevidys Gene Therapy Shows Sustained Benefits in Duchenne Muscular Dystrophy Patients

5 months ago

• Sarepta Therapeutics' Elevidys demonstrates sustained benefits and disease stabilization in ambulatory Duchenne muscular dystrophy (DMD) patients, according to Phase 3 EMBARK trial results. • Crossover-treated patients showed a 2.34-point improvement on the North Star Ambulatory Assessment (NSAA) compared to matched external controls after 52 weeks of Elevidys treatment. • Patients treated with Elevidys in Part 1 of EMBARK maintained clinically meaningful improvements in NSAA, Time to Rise (TTR), and 10-meter walk/run (10MWR) at two years. • Muscle biopsies showed consistent micro-dystrophin expression, and MRI scans indicated minimal muscle pathology progression, reinforcing Elevidys's long-term efficacy and safety.